Navigation Links
ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
Date:6/21/2010

DEERFIELD, Ill., June 21 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that ACTOplus met® XR, an extended-release version of the combination medication ACTOplus met® (pioglitazone HCl and metformin HCl), is now available in United States (U.S.) pharmacies for the treatment of type 2 diabetes as an adjunct to diet and exercise. This once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets – is the first and only oral antidiabetic fixed-dose combination medication with the extended-release formulation of metformin.

ACTOplus met XR combines ACTOS® (pioglitazone HCL) and metformin, two widely used diabetes medications with established safety profiles, in a single tablet. ACTOS directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced in the liver. These medications work in combination, along with diet and exercise, to help patients with type 2 diabetes improve glycemic control.

Takeda is the inventor and developer of ACTOS, which was launched commercially in the U.S. in 1999. ACTOS has been an effective and appropriate treatment for people living with type 2 diabetes, and has been prescribed for more than 10 million patients to date.

Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc. and licensed to Takeda Pharmaceutical Company Limited.

ACTOplus met® (pioglitazone HCl and metformin HCl) <
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
3. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
10. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
11. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 RadiologyAuction will have their first auction starting ... demonstrations at the end of the auction on May ... and Fuji Cr,s, Agfa and Sony, printers and GE ... Various imaging equipment will be available at later auctions ... years of buying and selling imaging equipment, the brokers ...
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
(Date:5/4/2015)... May 4, 2015  Makindus, Inc. a specialty pharmaceutical ... European Medicines Agency (EMA) has granted orphan drug designation ... Stargardt,s Disease. "We are extremely pleased to ... Stargardt,s disease in place for Europe ... the United States for which ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2
... GRASS VALLEY, Calif., Jan. 18, 2011 Eigen, a ... announced the completion of the company,s restructuring plan designed ... billion urology medical device marketplace. The company ... is now positioned with a unified management team and ...
... 2011 Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... today announced financial results of the three months ended ... the noninvasive treatment of cardiovascular diseases. In addition, the ... VasoHealthcare , commenced operations on July 1, 2010 under ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 The ... for assessing and treating children with feeding and ... the course of 20 years through the clinical ... Kay Toomey , in conjunction with colleagues from ... dieticians, and speech pathologists. Education Resources Inc. is ...
(Date:5/5/2015)... NJ (PRWEB) May 05, 2015 Texting has ... is no surprise that some physicians text as a way ... we urge providers who are doing so to assure medical ... does not come without risk! When providers transmit protected ... mobile devices, they run the risk of violating the Health ...
(Date:5/5/2015)... Curly Hair Solutions™ is delighted to introduce the ... Mist. The collection has every curl type covered, ... loose to medium body curls is exposure to the ocean ... fancying the ocean breeze needn’t leave their bathroom. , ... Mist produces the same invigorating freshness one gets when exposed ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 Lauren ... goods retailer City Sports , was named one ... and active lifestyle industry by the SportsOneSource ... , Ms. Blanda, 33, is one of 40 executives ... Sporting Goods Business magazine) recognized for exceptional achievement in ...
(Date:5/4/2015)... Parlin dentist, Dr Mariana Blagoev is extending her ... to participate and win a laptop. , Dr. Blagoev created ... good deeds and share them on her Facebook page. By ... teach them to be kind and compassionate when they mature ... years of age and under. Youths are urged to submit ...
Breaking Medicine News(10 mins):Health News:Commission on Dietetic Registration Approves Two Pediatric Feeding Courses Offered by Education Resources Inc. 2Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:Curly Hair Solutions Introduces New Revolutionary Product: Curl Keeper Beach Mist 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 3Health News:10 More Days To Enter Good Deed Contest 2
... a connection with obesity risks as they grow up, more so, in ... team of researchers led by Sarah E. Anderson, M.S., from Tufts University ... and 417 men - who underwent assessment four times between 1983 and ... during the beginning of the study, and were in the age group ...
... deteriorate as they progress through puberty, reveals a new ... levels of insulin, however, remain unchanged in their Caucasian ... plays a crucial role in determining the individual risk ... study was conducted by Dr. Geoff Ball and his ...
... Ramadoss said that India is crowned as the diabetic capital. ... national programme for prevention and control of cardiovascular disease, //stroke ... meeting. ,He submitted a draft of the programme ... to make it workable. ,The programme’s main ...
... global network of virus, spyware and spam analysis centers, have warned ... across the internet.// ,This letter claims that lipstick causes ... contain a dangerously high level of lead which can cause cancer. ... claims are not true. ,Sopho has asked the users ...
... incidence of pregnancy complications, more specifically preeclampsia related//, ... Obstetrics and Gynecology. ,Preeclampsia, a pregnancy-related ... (high levels of protein in the urine). Swelling ... seen. If left unattended, the condition can worsen ...
... the women especially the pregnant women about the risks ... as selective serotonin re-uptake inhibitors //(SSRIs) affect the fetus. ... called persistent pulmonary hypertension in babies born to women ... The recent study links SSRIs to this fatal condition ...
Cached Medicine News:Health News:African American Children More Pone to Develop Diabetes 2
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: